Dyslipidemia Archives - Endocrinology Advisor

Dyslipidemia

Updated NLA Guidance Identifies Patients in Which PCSK9i Use Provides Reasonable Value

The National Lipid Association (NLA) has released updated guidance for clinicians on identifying patients for which proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor therapy would provide reasonable value. Currently, two PCSK9 therapies have been approved by the Food and Drug Administration. Alirocumab is indicated as an adjunct to diet, alone or in combination with…

Next post in News